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ABSTRACT
Marrow fibrosis is considered a poor prognostic factor in patients with myelodysplastic syndrome (MDS). The
affect of fibrosis on outcomes after hematopoietic cell transplantation (HCT) in patients with MDS has not
been examined. We performed a retrospective analysis in 471 patients with MDS or acute myeloid leukemia
with multilineage dysplasia arising from MDS, 113 with and 358 without marrow fibrosis, who received
myeloablative allogeneic HCT. Post-HCT follow-up was 0.3–10 years (median, 3.6 years) for patients with, and
0.6–12 years (median, 5 years) for patients without fibrosis. Engraftment was significantly delayed in patients
with fibrosis (hazard ratio [HR]  0.4; P < .001). Overall, there were no significant differences in overall
survival (OS), relapse-free survival (RFS), and nonrelapse mortality (NRM) between patients with and without
fibrosis. However, among patients with advanced disease (int-2 or high-risk disease by the International
Prognostic Scoring System), OS (P  .03), RFS (P  .04), and NRM (P  .04) were inferior when marrow
fibrosis was present. Given that marrow fibrosis is a poor prognostic factor for patients with MDS, and that it
does not appear to affect outcome of transplantation in patients with earlier-stage disease but has a negative
impact on outcome for patients with advanced disease, patients with earlier-stage MDS and marrow fibrosis
might be considered for HCT earlier than their disease stage would normally dictate.
© 2007 American Society for Blood and Marrow Transplantation
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The term “myelodysplastic syndrome” (MDS) de-
cribes a heterogeneous group of clonal hematopoietic
iseases. Various disease parameters have been used to
ssign prognostic relevance. The French-American-
ritish (FAB) classiﬁcation uses the proportion of my-
loblasts in marrow and blood for disease staging
1,2]. The World Health Organization (WHO) clas-
iﬁcation, in addition, considers the number of cell
ineages exhibiting dysplasia as a criterion for staging
3]. The International Prognostic Scoring System
IPSS) includes myeloblast percentage, karyotypic ab- dormalities, and the number of peripheral blood cy-
openias as parameters for disease classiﬁcation and
rognosis [4]. Recently, a red blood cell transfusion
equirement has been identiﬁed as a risk factor [5],
nd additional risk factors have been proposed [5-8].
owever, none of the current classiﬁcation schemes
nclude marrow ﬁbrosis as a risk parameter, although
systematic deﬁnition of MDS with ﬁbrosis has been
roposed [9].
The reported incidence of marrow ﬁbrosis among
atients with de novo MDS ranges from 2% to 50%,
nd is as high as 80% with secondary MDS [10-12]
epending on what degree of morphologically recog-
345
n
p
5
3
o
ﬁ
t
w
m
s
d
w
m
t
t
f
c
s
w
w
c
r
a
w
O
c
(
p
(
ﬁ
i
f
t
t
r
m
p
a
s
s
c
s
i
p
P
P
T
M
o
e
o
d
T
4
ﬁ
p
p
H
a
r
c
i
p
e
s
o
d
a
T
N
A
S
E
D
W
D
I
C
M
*
B. L. Scott et al.346izable changes are considered. In a series of 170
atients with MDS reported by Steensma et al. [9],
0% had grade 1 or 2 marrow ﬁbrosis, 10% had grade
ﬁbrosis, and  2% had grade 4 ﬁbrosis, considering
nly reticulin deposits. The clinical signiﬁcance of
brosis is a matter of controversy [13]. In a retrospec-
ive analysis by Maschek et al. [14], 61 of 352 patients
ith primary MDS (17.3%) had marrow ﬁbrosis. The
edian survival was 9.6 months in patients with ﬁbro-
is and 17.4 months in patients without ﬁbrosis. The
ifferences in survival were more profound in patients
ith refractory anemia, with a median survival of 10
onths in patients with ﬁbrosis and 28.9 months in
hose without ﬁbrosis. Multivariate analysis showed
hat the degree of ﬁbrosis was an adverse prognostic
actor above and beyond the risk implied by the FAB
lassiﬁcation [12]. Several additional studies arrived at
imilar conclusions, showing that in MDS patients
ith otherwise comparable disease, life expectancy
as only 9–10 months for those with marrow ﬁbrosis,
ompared with 17–18 months in those without mar-
ow ﬁbrosis [12,14-16]. Published data do not provide
deﬁnitive explanation of why patients with MDS
ith marrow ﬁbrosis have a shorter life expectancy.
ne retrospective analysis found an insigniﬁcant in-
rease in transformation to acute myeloid leukemia
AML) in MDS patients with marrow ﬁbrosis com-
ared with MDS patients without marrow ﬁbrosis
36.1% vs 31.6%) [14]. A negative impact of marrow
brosis on clinical outcomes has also been described
n other hematopoietic malignancies [17,18].
The only current therapy with curative potential
or patients with MDS is hematopoietic cell transplan-
ation (HCT). The optimum timing of HCT is con-
roversial; it is generally delayed in patients with low-
isk MDS as deﬁned by IPSS criteria [19]. However, if
arrow ﬁbrosis is associated with more rapid disease
rogression than suggested on the basis of currently
ccepted MDS classiﬁcations, then those patients
hould be considered for HCT at an earlier disease
tage than that proposed on the basis of the IPSS
lassiﬁcation (which does not consider marrow ﬁbro-
is) [4]. Here we present a retrospective analysis of the
mpact of marrow ﬁbrosis on the outcome of HCT in
atients with MDS.
ATIENTS AND METHODS
atients
Patient and disease characteristics are summarized in
able 1. A total of 471 patients with MDS, a history of
DS who had transformed to acute leukemia (tAML),
r chronic myelomonocytic leukemia (CMML) were
nrolled in the present study. (CMML accounted for 5%
f the patients and was included in the cohort despite the
ebate regarding the classiﬁcation of CMML [9,20].) the patients ranged in age from 1 to 69 years (median,
8 years); 267 were male and 204 female. Marrow
brosis (as deﬁned in the following section) was
resent in 113 patients and absent in 358 patients. All
atients underwent transplantation at the Fred
utchinson Cancer Research Center between Febru-
ry 1993 and November 2003. All patients were en-
olled in institutional review board–approved proto-
ols active at the time of enrollment.
Only patients with at least 1 ﬁbrosis and dysplasia
nvolving at least 10% of nucleated cells of any hemato-
oietic lineage other than solely the megakaryocytic lin-
age qualiﬁed for inclusion as MDS with ﬁbrosis. Fibro-
is was determined by reticulin and trichrome staining
n good-quality bone marrow biopsy specimens. The
egree of ﬁbrosis was based on the Manoharan scale
pplied to marrow biopsy specimens obtained pre-
able 1. Patient and Disease Characteristics
Characteristic
Fibrosis
Yes No
o. of patients 113 358
ge, median (range), years 50 (1-66) 47 (1-69)
ex, M/F, no. 56/57 211/147
tiology, no. (%)
Primary 83 (73) 264 (74)
Secondary 30 (27) 94 (26)
isease duration, median (range),
months 7 (1-179) 7 (0-159)
HO stage, no. (%)
< 5% marrow myeloblasts; no
peripheral blasts 32 (28) 127 (35)
RA 7 41
RARS 2 7
RCMD 18 56
MDS-U 1 11
5q Syndrome 4 12
RAEB-1 21 (29) 40 (11)
RAEB-2 14 (12) 42 (12)
TAML 38 (34) 133 (37)
CMML-1 5 (4) 6 (2)
CMML-2 3 (3) 10 (3)
egree of marrow fibrosis, no. (%)
1 57 (50) N/A
2 25 (22) N/A
3 22 (20) N/A
4 9 (8) N/A
PSS risk group, no. (%)
Low 11 (10) 29 (8)
Intermediate-1 28 (25) 101 (28)
Intermediate-2 42 (37) 97 (27)
High 32 (28) 131 (37)
ytogenetic risk group, no. (%)*
Good 44 (39) 171 (48)
Intermediate 23 (20) 63 (18)
Poor 46 (41) 124 (34)
DS-U indicates unclassiﬁed MDS; N/A, nonapplicable; RA, re-
fractory anemia with ring sideroblasts; RCMD, refractory cyto-
penia with multilineage dysplasia.
Five patients without ﬁbrosis had no cytogenetic data available.ransplantation (within 25 days of receipt of donor
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Marrow Fibrosis Affects Transplantation Outcome in MDS 347tem cells) [21]. The grading used the proportion and
istribution of ﬁne and coarse reticulin ﬁbers, as
ell as the presence or absence of collagen. Grade 1
escribed a mild and generally localized increase in
eticulin ﬁbers; grade 2 described a more diffuse
etwork, including coarse ﬁbers; grade 3 showed
redominantly coarse ﬁbers; and grade 4 included
ollagen deposition [22]. The bone marrow aspirate
nd biopsy results were reviewed by 4 separate pa-
hologists and veriﬁed by 1 pathologist (RCH) for
his study. The Philadelphia chromosome was ab-
ent in all patients as determined by standard karyo-
ype analysis. In addition, no patient had hepato-
plenomegaly, leukoerythroblastosis, or increased
egakaryocytic blasts. Patients with myeloprolifer-
tive diseases, megakaryocytic leukemia, agnogenic
yeloid metaplasia, and acute myeloﬁbrosis were
xcluded from this analysis.
Age and sex distributions were similar for patients
ith and without ﬁbrosis. Most patients were in an
dvanced disease category for refractory anemia with
xcess blasts (RAEB) and tAML as deﬁned by WHO
riteria [3], and were in the intermediate-2 or high-
isk groups based on IPSS criteria [4]. The distribu-
ion by cytogenetic risk as deﬁned by IPSS was similar
or the 2 groups. Among patients with  5% marrow
yeloblasts, the most common diagnosis was refrac-
ory cytopenias with multilineage dysplasia. Among
he 113 patients with ﬁbrosis, 28% had grade 3 or 4
brosis. There was no association between degree
f ﬁbrosis and cytogenetic risk group, and no par-
icular cytogenetic abnormalities were associated
ith ﬁbrosis. There was no correlation between
isease duration and severity of ﬁbrosis, or between
egree of ﬁbrosis and stage of disease as deﬁned by
he WHO (Table 2).
onditioning for Hematopoietic
ell Transplantation
Donor and transplant characteristics are summa-
ized in Table 3. In most patients, transplantation
onditioning consisted of busulfan (Bu), prescribed
ose 16  1 mg/kg, adjusted to achieve target steady-
tate levels of 600–900 ng/mL (tBu), plus cyclophos-
hamide (Cy) 2  60 mg/kg [23]. The remaining
able 2. Degree of Fibrosis by WHO Disease Category
WHO
Classification
Total No.
of Patients
Degree of Fibrosis [21],
No. of Patients (%)
1 2 3 4
5% blasts 32 13 (40) 11 (34) 5 (16) 3 (9)
AEB-1 21 11 (52) 4 (19) 4 (19) 2 (10)
AEB-2 14 7 (50) 3 (21) 2 (14) 2 (14)
AML 38 22 (58) 7 (18) 8 (21) 1 (3)
MML-1 5 1 (20) 0 3 (60) 1 (20)r
MML-2 3 3 (100) 0 0 0atients were conditioned with tBu combined with
udarabine 4  30 mg/m2; Cy 2  60 mg/kg, plus
2–14.4 Gy total body irradiation (TBI); tBu Cy 2 
0 mg/kg plus 12 Gy TBI; or Bu 7 mg/kg plus 12 Gy
BI [24-27].
ources of Hematopoietic Stem Cells
Stem cell donors were genotypically HLA-identi-
al siblings (n  196), HLA-matched family members
ther than siblings (n  6), HLA-nonidentical family
embers (n  20), HLA-matched unrelated donors
n  175), HLA-nonidentical unrelated donors (n 
0), or syngeneic twins (n 4) (Table 3). Beginning in
995, HLA identity required matching for HLA-A,
B, -C, -DR, and -DQ antigens as determined by
erology; beginning in 1998, HLA identity was de-
ermined by intermediate or high-resolution typing
28]. A total of 216 patients received granulocyte
olony-stimulating factor (G-CSF)-mobilized pe-
able 3. Donor and Transplant Characteristics
No. of Patients (%)
Characteristic Fibrosis No Fibrosis
VHD prophylaxis
MTX/CSP 91 (81) 254 (71)
MTX/FK506 ( CSP) 5 (4) 45 (13)
MTX/CSP  antibody* 10 (9) 26 (7)
CSP/MMF 4 (4) 7 (2)
CSP/steroid 1 (1) 19 (5)
CSP/steroid  ATG* 1 (1) 0
CSP/rapamycin 0 4 (1)
None† 1 (1) 3 (1)
onor
Related 59 (52) 167 (47)
HLA-identical sibling 49 147
Mismatched family member 8 12
HLA-matched family member 1 5
Syngeneic 1 3
Unrelated 54 (48) 191 (53)
HLA-matched 42 133
Mismatched 12 58
tem cell source
Peripheral blood 52 (46) 164 (46)
Marrow 60 (53) 194 (54)
Cord 1 (1) 0
onditioning regimen
tBuCy 70 (62) 203 (57)
BuFlu 10 (9) 17 (5)
BuTBI 16 (14) 60 (17)
CyTBI 14 (12) 70 (20)
FluCyTBI 0 1
BuVP16 0 1
BuCyTBI 3 (3) 6 (2)
u indicates busulfan; Cy, cyclophosphamide; CSP, cyclosporine;
FK506, tacrolimus; Flu, ﬂudarabine; MMF, mycophenolate
mofetil; MTX, methotrexate; TBI, total body irradiation; tBu,
targeted BU; VP16, etoposide.
Antithymocyte globulin (ATG) or humanized anti-tac (HAT).
Syngeneic donor.ipheral blood progenitor cells (PBPCs), 254 pa-
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B. L. Scott et al.348ients received bone marrow, and 1 patient received
ord blood. Stem cells were infused within 24 hours
f completion of TBI or within 36–48 hours of the
ast dose of chemotherapy. All recipients received T-
ell–replete grafts. ABO-incompatible grafts under-
ent red blood cell depletion or plasma reduction,
epending on pretransplantation recipient/donor
BO isoagglutinin titers. The marrow cell dose was
.5–8.3  108 mononuclear cells/kg for patients with
brosis (median, 2.6  108 mononuclear cells/kg) and
.4–11.6  108 mononuclear cells/kg for patients
ithout ﬁbrosis (median, 2.73  108 mononuclear
ells/kg). The corresponding values for those patients
ho received PBPCs were 0.02–21.92  106 CD34
ells/kg (median, 7.2  106 CD34 cells/kg) and
.16–32.4  106 CD34 cells/kg (median, 6.78  106
D34 cells/kg), respectively.
raft-versus-Host Disease Prophylaxis
nd Therapy
Most of the patients received intravenous metho-
rexate and cyclosporine for graft-versus-host disease
GVHD) prophylaxis [29]. Other GVHD prophylaxis
egimens used are summarized in Table 3. Acute
VHD (aGVHD) was diagnosed and graded accord-
ng to consensus criteria [30]. Chronic GVHD
cGVHD) was diagnosed as clinically limited or ex-
ensive (requiring immunosuppressive therapy) using
reviously published criteria [31,32]. Therapy for es-
ablished GVHD consisted of various agents, accord-
ng to protocols that were active at the time [33-35].
ngraftment and Rejection
The day of engraftment was deﬁned as the ﬁrst of
days on which the absolute neutrophil counts re-
ained 0.5 109/L. Evidence of graft rejection was
ought in patients who failed to reach 0.5  109
eutrophils/L by day 28 and in patients with sustained
eclines in counts after initial recovery. When donor
nd host were of different sex, ﬂuorescent in situ
ybridization (FISH) with X and Y chromosome
robes was used to determine donor versus host origin
f marrow mononuclear cells [36]. When donor and
ost were of the same sex, DNA from marrow mono-
uclear cells was ampliﬁed by polymerase chain reac-
ion (PCR) and analyzed for variable-number tandem
epeats to identify host and donor markers [37,38].
elapse
All patients received marrow evaluations on days
8, 56, and 84 ( 3 days) after HCT by cytogenetic,
ow cytometric, and morphologic analyses. Subse-
uently, the same studies were performed annually
nd as clinically indicated. Relapse was deﬁned as the
resence of dysplastic cells by ﬂow cytometry, mor-
hologic evidence of dysplastic myeloblasts, or the 4eappearance of cytogenetic abnormalities identiﬁed
efore transplantation [39,40]. In patients with mor-
hologic, hematologic, or cytogenetic evidence of re-
apse, relapse rather than graft rejection was consid-
red the cause of failed engraftment.
auses of Death
In patients with disease recurrence, relapse was
isted as the primary cause of death regardless of other
ssociated events. In patients with GVHD requiring
mmunosuppressive therapy who subsequently died
rom infection, GVHD and infection were considered
he causes of death. Infection was considered the cause
f death when it occurred in the absence of clinically
igniﬁcant GVHD or relapse. Multiorgan failure was
dentiﬁed as the cause of death when it occurred in the
bsence of relapse and was thought to not primarily
esult from preceding GVHD or infection. Graft re-
ection (as deﬁned earlier) was considered the cause of
eath if patients died of complications related to poor
arrow function and there was no evidence of relapse
nd no evidence of GVHD, but only if the patient
urvived beyond day 28 posttransplantation.
tatistical Analysis
Results were analyzed as of November 30, 2005.
verall survival (OS) and progression-free survival
ere estimated using the Kaplan-Meier method [41].
umulative incidence curves for relapse, nonrelapse
ortality (NRM), and engraftment were estimated
ccording to methods described by Gooley et al. [42].
eaths were treated as competing events in the anal-
ses of engraftment, GVHD, and progression. Hazard
atios (HRs) were estimated using Cox regression
odels [43] and adjusted for WHO classiﬁcation
5% marrow myeloblasts, RAEB-1, RAEB-2,
AML, or CMML), IPSS group (low/int-1 or int-2/
igh), and donor status (related or unrelated). HRs 
indicate worse outcomes with ﬁbrosis, with the ex-
eption of engraftment, where HRs  1 indicate
orse outcomes with ﬁbrosis.
ESULTS
ngraftment
Among the 113 patients with ﬁbrosis, 11 (10%)
ied before day 28 without evidence of GVHD and
ere considered not evaluable for engraftment. Four
atients (4%) died with graft failure or persistent dis-
ase at 38–2202 days. The median time to engraft-
ent in the remaining 98 patients was 28 days (range,
0–80 days). Among the 358 patients without ﬁbrosis,
3 patients (6%) died before day 28 without evidence
f GVHD and were considered not evaluable for en-
raftment. Five patients (1%) died with graft failure at
6–343 days. The median time to engraftment in the
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Marrow Fibrosis Affects Transplantation Outcome in MDS 349emaining 330 patients was 17 days (range, 10–33
ays). Engraftment was signiﬁcantly delayed in pa-
ients with ﬁbrosis compared with those without ﬁ-
rosis (P  .0001), and the delay in engraftment cor-
elated with the degree of ﬁbrosis (Figure 1). This
elay in engraftment occurred regardless of stem cell
ource (HR  0.56, P  .0005 for marrow and HR 
.28, P .0001 for PBPCs). Graft failure as a cause of
eath was more common in patients with marrow
brosis (5% vs 2%), but this difference did not reach
tatistical signiﬁcance (P  .09).
igure 1. Marrow ﬁbrosis and granulocyte engraftment. Time to
ngraftment in patients without ﬁbrosis (n  358), in those with
rades 1 or 2 ﬁbrosis (n  82), and in those with grades 3 or 4
brosis (n  31).
able 4. Transplant Outcomes for 471 Patients in relation to Fibrosis
atient Cohort Fibrosis
(yes/no; grade)
OS
HR*,†
(95% CI)
P
Value*
HR*,†
(95% CI
ll patients
No (n  358) 1.0 1.0
Yes (n  113) 1.21 (0.9-1.6) .16 1.24 (1.0-
ll patients
No (n  358) 1.0 1.0
1,2 (n  82) 1.23 (0.9-1.7) .17 1.30 (1.0-
3,4 (n  31) 1.14 (0.7-1.8) .58 1.08 (0.7-
PSS low/int-1 patients
No (n  130) 1.0 1.0
Yes (n  39) 0.83 (0.5-1.5) .52 0.94 (0.5-
PSS int-2/high patients
No (n  228) 1.0 1.0
Yes (n  74) 1.39 (1.0-1.9) .03 1.38 (1.0-
rimary MDS
No (n  339) 1.0 1.0
Yes (n  81) 1.16 (0.8-1.6) .35 1.16 (0.9-
econdary MDS
No (n  16) 1.0 1.0
Yes (n  28) 1.24 (0.6-2.7) .59 1.66 (0.8-
Adjusted for WHO group (5% marrow myeloblasts, RAEB-1,
(related, unrelated).
HR  1 means worse outcome with ﬁbrosis.
HR  1 means worse outcome with ﬁbrosis.VHD
Of the 113 patients with marrow ﬁbrosis, 112 had
llogeneic donors; 77 of these patients (69%) devel-
ped grade II–IV acute GVHD, including 29 (26%)
ith grade III–IV GVHD. Of the 358 patients with-
ut marrow ﬁbrosis, 355 had allogeneic donors and
68 (75%) developed grade II–IV GVHD, including
9 (28%) with grade III–IV GVHD. The crude inci-
ence of chronic GVHD was 43% (48 of 112) in
atients with ﬁbrosis and 48% (169 of 355) in patients
ithout ﬁbrosis. The degree of marrow ﬁbrosis did
ot have an impact on the incidence or severity of
VHD.
elapse
Thirty-one patients with ﬁbrosis (27%) experi-
nced relapse between 23 and 2743 days (median, 128
ays) after HCT, and 27 died secondary to relapse.
our patients are alive and in remission, after with-
rawal of immunosuppressive drugs in 2 and after
onor lymphocyte infusion (DLI) in the other 2. Sev-
nty-eight patients without ﬁbrosis (22%) experienced
elapse between 19 and 2966 days (median, 143 days)
fter HCT; 73 died, and 5 are alive in remission after
ithdrawal of immunosuppression and DLI. As has
een reported previously in patients with MDS
23,44], the probability of relapse correlates with dis-
ase stage, speciﬁcally the proportion of pretransplan-
ation marrow myeloblasts. Results of an analysis of
elapse-free survival (RFS) are summarized in Table 4.
NRM Engraftment
P
Value*
HR*,†
(95% CI)
P
Value*
HR*,‡
(95% CI)
P
Value*
1.0 1.0
.11 1.17 (0.8-1.6) .35 0.40 (0.3-0.5) < .0001
1.0 1.0
.07 1.15 (0.8-1.7) .47 0.43 (0.3-0.6) < .0001
.75 1.23 (0.7-2.1) .46 0.33 (0.2-0.5) < .0001
1.0 1.0
.82 0.62 (0.3-1.3) .18 0.43 (0.3-0.6) < .0001
1.0 1.0
.04 1.51 (1.0-2.2) .04 0.39 (0.3-0.5) < .0001
1.0 1.0
.34 1.16 (0.8-1.7) .46 0.38 (0.3-0.5) < .0001
1.0 1.0
.20 1.16 (0.4-3.0) .76 0.55 (0.3-1.2) .12
-2, t-AML, CMML), IPSS (low/int-1, int-2/high), donor statusRFS
)
1.6)
1.7)
1.7)
1.6)
1.9)
1.6)
3.6)
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B. L. Scott et al.350verall, there was no signiﬁcant difference in RFS
etween patients without or with concomitant mar-
ow ﬁbrosis (HR  1 vs 1.24; P  .11) (Figure 2A).
owever, in patients with more advanced disease
tates as deﬁned by the IPSS (int-2 or high risk), RFS
as signiﬁcantly worse in those with marrow ﬁbro-
is than in those without ﬁbrosis (HR  1.38 vs 1.0;
 .04).
Although the degree of marrow ﬁbrosis overall
ad no signiﬁcant impact on relapse (Figure 2B), there
as a suggestion of decreased relapse rates in patients
ith grades 3 and 4 ﬁbrosis compared with those with
rades 1 and 2 ﬁbrosis (HR 0.49; P not signiﬁcant
NS]). This difference was insigniﬁcant when grade 4
brosis was compared with grade 1 ﬁbrosis (HR 
.3; PNS). Conversely, the rate of NRM was higher
HR  1.7; P  NS) in patients with grade 4 ﬁbrosis
han in those with grade 1 ﬁbrosis. However, the
ample size of patients with grade 4 ﬁbrosis was small,
nd thus no deﬁnitive conclusions could be drawn.
urvival
Among the patients with ﬁbrosis, 39 (35%) were
igure 2. RFS and relapse incidence by degree of marrow ﬁbrosis.
A) RFS in patients without ﬁbrosis, with grade 1 or 2 ﬁbrosis, and
ith grade 3 or 4 ﬁbrosis. (B) Relapse rates with corresponding
egree of ﬁbrosis as graded by the Manoharan scale: grade 1, n 
7; grade 2, n  25; grade 3, n  22; grade 4, n  9.live with a median follow-up of 3.6 years. Among hhose without ﬁbrosis, 136 (38%) were alive with a
edian follow-up of 5 years. Analysis of OS is sum-
arized in Table 4. Among all patients, OS was not
igniﬁcantly different between those with and without
brosis (HR 1.21; P .16) (Figure 3A). The degree
f marrow ﬁbrosis did not signiﬁcantly affect survival.
S was superior in patients with early-stage disease as
eﬁned by the FAB, WHO, or IPSS regardless of the
resence of ﬁbrosis. For patients with IPSS int-1 or
igure 3. Impact of marrow ﬁbrosis on transplantation outcome.
A) OS in patients without ﬁbrosis, with grades 1 or 2 ﬁbrosis, and
ith grades 3 or 4 ﬁbrosis. (B) OS in int-1 or low-risk patients with
n  39) and without (n  130) ﬁbrosis. (C) OS in IPSS int-2 or
igh-risk patients with (n  74) and without (n  228) ﬁbrosis.
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Marrow Fibrosis Affects Transplantation Outcome in MDS 351ow-risk MDS, OS was not signiﬁcantly different
hen concurrent marrow ﬁbrosis was present (HR 
.83; P  .52) (Figure 3B). However, in patients with
dvanced disease (IPSS int-2 or high risk), OS was
igniﬁcantly lower in those with ﬁbrosis than in those
ithout ﬁbrosis (HR  1.39; P  .03) (Figure 3C).
auses of Death
Causes of death are summarized in Table 5. Re-
apse was the most common cause of death in all
ohorts except the small group of patients with grade
ﬁbrosis who had a high incidence of multisystem
rgan failure after pretransplantation conditioning.
or the entire cohort, NRM was not signiﬁcantly
ffected by the degree of ﬁbrosis. The day-100 and
-year incidences of NRM were 27% and 29%, re-
pectively, for patients with grade 1 and 2 ﬁbrosis, and
4% and 44%, respectively, for those with grade 3 and
ﬁbrosis (HR  1.0 vs 1.17; P  .35) (Figure 4).
owever, in patients with advanced disease (IPSS
nt-2 or high risk), NRM was signiﬁcantly higher in
hose with concomitant marrow ﬁbrosis than in those
igure 4. Marrow ﬁbrosis and NRM. NRM in patients without
able 5. Causes of Death
Cause of Death (No. of Patients)
All
Patients
(n  113) 1 (n  57)
ll causes 74 41
elapse 27* (36%) 17 (41%)
nfection 17 (23%) 10 (24%)
VHD*  infection 14 (19%) 7 (17%)
rgan failure  infection  GVHD 10 (14%) 4 (10%)
yocardial infarction 1 (1%) 0
raft failure 4† (5%) 2 (5%)
nknown 1‡ (1%) 1‡ (2%)
Four patients who relapsed after transplantation are alive in remis
11 patients died prior to day 28 without evidence of GVHD and
Patient’s consent for data collection was withdrawn.
Five patients who relapsed after transplantation are alive and in rrbrosis, with grade 1 or 2 ﬁbrosis, and with grade 3 or 4 ﬁbrosis.ithout ﬁbrosis (HR  1.51 vs 1.0; P  .04), suggest-
ng an interaction between ﬁbrosis and other disease
arameters.
ISCUSSION
The prognosis of patients with MDS is deter-
ined in particular by the proportion of myeloblasts
n marrow and blood, clonal cytogenetic abnormali-
ies, and peripheral blood cytopenias [4]. Other fac-
ors, including the need for red blood cell transfusions
45] and immunophenotypic aberrancies of marrow
ells [7], have recently been reported. Whether the
resence of marrow ﬁbrosis is a separate risk factor is
nder debate. Most reports indicate a decreased life
xpectancy for patients with MDS who have marrow
brosis. The negative effect of ﬁbrosis on life expect-
ncy has been reported to be more profound in pa-
ients with early-stage MDS [9,13,14]. In view of the
ery encouraging transplantation outcomes in patients
ith marrow ﬁbrosis of different etiologies [46], we
ere interested in determining transplantation success
n patients with MDS and associated marrow ﬁbrosis.
Various outcomes after HCT were affected by the
resence of marrow ﬁbrosis. There was a signiﬁcant
elay in engraftment in patients with ﬁbrosis that
orrelated with the degree of ﬁbrosis, conﬁrming re-
ults of a previous report on a smaller number of
atients [47]. But these results were in contrast to
hose of a retrospective comparison between 203 pa-
ients with ﬁbrosis and 203 concurrent patients with-
ut marrow ﬁbrosis that showed no difference in time
o engraftment [48]. Conceivably, the differences were
elated to the fact that this earlier study included a
ange of diagnoses (chronic myeloid leukemia, acute
ymphoid leukemia, non-Hodgkin’s lymphoma, and
thers) and was composed entirely of patients who
ith Fibrosis
MDS Without Fibrosis
(n  358)
y Degree of Fibrosis
n  25) 3 (n  22) 4 (n  9)
14 13 6 217§
(36%) 4 (31%) 1 (17%) 73 (34%)
(29%) 3 (23%) 0 15 (7%)
(29%) 3 (23%) 0 83 (38%)
(7%) 1 (8%) 4 (67%) 36 (17%)
0 1 (8%) 0 3 (1%)
0 1 (8%) 1 (17%) 5 (2%)
0 0 0 2‡ (1%)
ot evaluable for engraftment.
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sion.
were neceived marrow as the source of stem cells. However,
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B. L. Scott et al.352he source of stem cells did not appear to be a signif-
cant factor in the present analysis. Although marrow
brosis correlated with a delay in engraftment, this
as not associated with an increased incidence of early
eath related to bleeding or infection. There was a
uggestion that patients with higher grades of ﬁbrosis
ere at lower risk for relapse. This is likely explained
y the difference in distribution by WHO category
mong the different grades of ﬁbrosis. Speciﬁcally,
atients with tAML or CMML-2 were more likely to
ave grade 1 ﬁbrosis rather than grade 3 or 4 ﬁbrosis.
atients with advanced-stage disease as classiﬁed by
he WHO system were unlikely to have survived long
nough to develop an advanced degree of ﬁbrosis.
lternatively, patients with both advanced-stage dis-
ase (as determined by the WHO) and advanced de-
ree of ﬁbrosis may not have been referred for trans-
lantation. Patients with advanced disease (IPSS
ategory int-2 or high risk) and concurrent marrow
brosis had a signiﬁcantly higher NRM, lower OS,
nd lower RFS than patients of identical IPSS risk but
ithout marrow ﬁbrosis.
Increased nonrelapse morbidity and NRM in as-
ociation with increased degrees of marrow ﬁbrosis
ave also been suggested in patients who underwent
CT for myeloproliferative diseases [46]. Although
he basis of this association is debatable, one possibil-
ty is that higher degrees of ﬁbrosis in the marrow are
aralleled by a greater likelihood of ﬁbrosis in other
rgans (eg, liver, lungs), making these organs more
usceptible to regimen-related toxicity after HCT.
ecause all patients in this analysis had been referred
or HCT, we cannot exclude the possibility that a
ertain selection had occurred, including the consid-
ration of marrow ﬁbrosis. However, regardless of
eferral bias, if MDS progresses more rapidly in pa-
ients with marrow ﬁbrosis, and if, as suggested by the
ata, the presence of ﬁbrosis has an increasingly neg-
tive impact on transplantation outcome in patients
ith more advanced/higher-risk disease (as deter-
ined by IPSS criteria), then patients with MDS and
brosis should be considered for HCT while they
ave less advanced disease, when an effect of ﬁbrosis
n transplantation outcome is less likely. Whether this
ssessment needs to be modiﬁed, depending on how
ome recently developed nontransplantation strategies
ffect the course of MDS and the impact of marrow
brosis, remains to be determined [49,50].
A more basic question is why patients with MDS
evelop marrow ﬁbrosis and how such a process might
lter the pathophysiology of MDS. Studies in patients
ith chronic idiopathic myeloﬁbrosis have shown that
arrow ﬁbrosis is a reactive process [51], and stroma
ells in patients with MDS are not part of the disease
lone [52]. The increased production of reticulin and
ollagen by marrow ﬁbroblasts appears to be in re-
ponse to such factors as transforming growth factor 53,54], basic ﬁbroblast growth factor [55], and plate-
et-derived growth factor [56], among others, derived
rom clonal cells. The secondary effects of this process
n hematopoiesis and possible positive feedback loops
eading to disease progression are currently under
nvestigation. Conceivably, interference with the pro-
uction or function of ﬁbrogenic cytokines might slow
he disease process.
In summary, available data suggest that patients
ith MDS and concurrent marrow ﬁbrosis tend to
ave a shorter life expectancy than those without ﬁ-
rosis. The negative impact of ﬁbrosis on survival
fter HCT appears to be restricted to patients with
dvanced-stage MDS. The potential role or mecha-
ism of marrow ﬁbrosis in disease progression is not
ell understood, and the tempo of progression is
ifﬁcult to predict. However, because the presence
r degree of marrow ﬁbrosis did not have a negative
mpact on OS or RFS after HCT in patients with
arly-stage MDS, but did so in patients with more
dvanced disease, patients with ﬁbrosis and early-
tage MDS should be considered for HCT earlier
han their disease stage (based on IPSS criteria)
ould suggest.
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